AbbVie joins the obesity drug race with $2.2b Gubra deal
Endpoints News - 03-Mar-2025The pharma giant bets on amylin therapy to enter the weight-loss market
Kyle LaHucik
Staff writer at Fierce Biotech
Staff writer at Fierce Biotech since May 2021. Prior to that, he spent 20 months reporting on the funding, M&A and public launches of tech, software and digital health companies as part of Mergermarket's Chicago bureau.
He completed Bachelor's in Journalism at University of Missouri.
Visit website: http://kylelahucik.com/
See also
FierceBiotech
Web resource providing the latest biotech news, articles, and resources related to biotech company news
Details last updated 10-Jul-2021
Articles written by Kyle LaHucik
Jupiter Bioventures: transforming early-stage science into biotech success
Endpoints News - 19-Nov-2024A $70m fund takes bold risks to validate ground-breaking ideas and reshape biotech innovation
Elevian has secured $40 million for anti-aging diseases and heart stroke
FierceBiotech - 17-Sep-2021$40 million for clinical research, lead program-stroke recovery focuses GDF11
Unity's senolytic drug reports positive phase 1 data in eye disease patients
FierceBiotech - 06-Jul-2021Begun phase 2 trial including patients with early stage of disease to test its safety and effectiveness
